Category - Developments

Developments

FDA approves Angel Medical implantable cardiac monitor

Closely-held Angel Medical Systems has received FDA premarket approval for the AngelMed Guardian System, an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The...

April 18, 2018

Developments

Novocure posts positive mesothelioma data; to file for FDA exemption

Novocure (NASDAQ:NVCR) reported positive top-line results from its STELLAR Phase 2 pilot trial in mesothelioma. The data demonstrate clinically meaningful improvements in overall survival and progression free survival...

April 17, 2018

Developments

Eiger BioPharma presents additional lonafarnib data in HDV

Eiger BioPharmaceuticals (NASDAQ:EIGR) presented additional positive lonafarnib (LNF) data from the LOWR hepatitis delta virus (HDV) program at the International Liver Congress 2018 in Paris. A sub-analysis of the LOWR...

April 17, 2018

Developments

Profound Medical Q2 Top Pick at Paradigm Capital

Paradigm Capital has made Profound Medical (TSXV:PRN; OTCQX:PRFMF) its second quarter Top Pick, saying the next three-to-four months are expected to be an accretive time for Profound. Analyst Rahul Sarugaser writes that...

April 12, 2018

Developments

CymaBay reports positive seladelpar data in PBC

CymaBay Therapeutics (NASDAQ:CBAY) presented new data from a second interim analysis of its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a type of liver disease that damages...

April 11, 2018

Developments

Arbutus and Roivant launch Genevant Sciences to develop RNA therapeutics

Arbutus Biopharma (NASDAQ:ABUS) and closely-held Roivant Sciences of Switzerland agreed to launch Genevant Sciences, a jointly-owned company focused on the discovery, development, and commercialization of a broad range...

April 11, 2018

Developments

BiondVax begins NIH-sponsored universal flu vaccine trial

BiondVax Pharmaceuticals (NASDAQ:BVXV) enrolled the first participant in a U.S. Phase 2 clinical trial of its universal flu vaccine candidate, M-001. The trial is sponsored by the U.S. National Institute of Allergy and...

April 11, 2018

Developments

CellAegis Devices begins U.S. pivotal trial of autoRIC device

Closely-held CellAegis Devices has enrolled the first patients in a U.S. pivotal trial of its autoRIC device, which automatically delivers remote ischemic conditioning (RIC) to provide a non-invasive, cardio-protective...

April 10, 2018

Developments

Ortho RTi posts positive Ortho-R data in rotator cuff repair

Ortho Regenerative Technologies (CSE:ORTH) reported positive preliminary MRI outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from...

April 2, 2018

Developments

BioLight completes first stage of sale of IOPtima

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the first stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the first...

March 29, 2018

Category - Developments

Subscribe